NCT03517423View on ClinicalTrials.gov

Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

December 1, 2022

Study Completion Date

August 29, 2023

Conditions
Epilepsy
Interventions
DRUG

Brivaracetam

An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.

Trial Locations (1)

H2X0C1

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER